Lentivirus‑mediated CD44s expression increases human basal cell carcinoma cell resistance against vismodegib

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Vismodegib (erivedge) for advanced Basal cell carcinoma.

Vismodegib (Erivedge) for advanced basal cell carcinoma.

متن کامل

Comparison of COX2 expression in radiation induced basal cell carcinoma and non-radiation induced basal cell carcinoma

Background: Radiation-induced basal cell carcinoma (BCC) can be multiple, large, and recurring, which complicates its treatment in some cases. According to reports on the role of cyclooxygenase 2 (COX2) inhibitors in the treatment or prevention of non-melanoma skin cancers and considering the fact that COX2 expression has not been evaluated in radiation-in...

متن کامل

Proteomic Analysis of Gene Expression in Basal Cell Carcinoma

Background: Basal Cell Carcinoma (BCC) is a type of non-melanoma skin cancer. Alteration in gene expression is the important event that happens in cancer cell. Detection of this event is possible by proteomics techniques. Methods: Normal and tumor tissues were taken from BCC patient. Total proteins were purified by standard methods, and proteins were separated by two-dimensional electrophoresis...

متن کامل

Targeted Therapy for Advanced Basal-Cell Carcinoma: Vismodegib and Beyond

Basal-cell carcinoma is a commonly occurring skin malignancy that has the potential to progress into locally invasive or resistant disease, as well as spread distantly. Due to advances in the molecular understanding of the disease over the last two decades, it has been discovered that the Hedgehog pathway plays an important role in the pathogenesis of this disease and can be exploited as a trea...

متن کامل

Investigational agents in metastatic basal cell carcinoma: focus on vismodegib.

Vismodegib (GDC-0449, 2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide, Erivedge™) is a novel first-in-human, first-in class, orally bio-available Hedgehog pathway signaling inhibitor of the G-protein coupled receptor-like protein smoothened (SMO) which was approved in the United States on January 2012. This signaling pathway is involved in the carcinogenesis of several ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Oncology Reports

سال: 2020

ISSN: 1021-335X,1791-2431

DOI: 10.3892/or.2020.7534